Navigation Links
NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

g postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards ... verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and ... prepared using the CLSI recommended “equal delta” method for linearity testing and is ...
(Date:7/24/2015)... , July 24, 2015 Ryan & ... filed in United States District Court for the Northern District ... persons or entities that purchased the common stock of Avalanche ... between July 31, 2014 and June 15, 2015, inclusive (the ... September 8, 2015, move the Court for appointment as a ...
(Date:7/24/2015)... July 24, 2015 Equity Research ... BioPharma Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. ... ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), and ... report on PDL BioPharma can be accessed at ... Composite ended at 5,146.41, down 0.49%, the Dow Jones ...
(Date:7/24/2015)... 2015 Orexigen Therapeutics, Inc. (Nasdaq: OREX ... second quarter 2015 on Thursday, August 6 before the ... business update and discuss the financial results in a ... Time (5:00 a.m. Pacific Time). The live ... 447-0521 (domestic) or (847) 413-3238 (international), participant code 40327229. ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... PARK, N.C., April 14, 2011 Talecris Biotherapeutics Holdings Corp. ... earnings release after the market closes on April 27, 2011. ... not be hosting a conference call to discuss its first ... Inspiration. Dedication. Innovation. Talecris Biotherapeutics ...
... NEW YORK, April 14, 2011 ... research report is available in its ... Market: DNA Probes And Biochips ... New Product Development Opportunities and ...
... at Penn State University, the Salk Institute for Biological ... recreating a schizophrenic patient,s own brain cells, which then ... dish. The method brings researchers a step closer to ... is expected to be used to study other mysterious ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips 2Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips 3Scientists recreate brain cells from skin cells to study schizophrenia safely 2Scientists recreate brain cells from skin cells to study schizophrenia safely 3
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... dinosaurs died and became fossilized, soft tissues didn't ... through a gradual replacement of all organic material ... State University paleontologist, however, could literally turn that ... professor of paleontology with a joint appointment at ...
... ATP (or GTP, a related energy currency) and transform ... myosin and dynein, proteins that use ATP to ferry ... proteins. The ATP-dependent assembly of actin or tubulin fibers ... march of white blood cells toward pathogens is powered ...
... Ph.D., Senior Bioinformatics Scientist at the European Molecular Biology ... they have identified a new primate-specific gene family that ... eight family members, the RGP gene cluster may help ... from the rest of the animal kingdom. , , ...
Cached Biology News:NC State scientist finds soft tissue in T. rex bones 2DNA Recombination and Repair—A New Twist to RecA Function 2Scientists document complex genomic events leading to the birth of new genes 2Scientists document complex genomic events leading to the birth of new genes 3
kismet (dK-20)...
... Thermo Hybaid's unique Electro-4 design allows ... the Electro-4 it is possible to run ... tank, by stacking up to four,horizontal gels. ... adjustable according to the number of gels ...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: